24 results
8-K
EX-99.1
CKPT
Checkpoint Therapeutics Inc
24 Jun 24
Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission
7:46am
any concerns about the clinical data package, safety, or labeling for the approvability of cosibelimab.
About Checkpoint Therapeutics
Checkpoint
8-K
EX-99.1
CKPT
Checkpoint Therapeutics Inc
10 May 24
Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates
8:45am
not state any concerns about the clinical data package, safety, or labeling for the approvability of cosibelimab. Checkpoint intends to seek
8-K
EX-99.1
CKPT
Checkpoint Therapeutics Inc
22 Mar 24
Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
8:52am
in the clinical data and safety package in support of cosibelimab. We look forward to providing additional updates in the second quarter.”
2023 and Recent … about the clinical data package, safety, or labeling for the approvability of cosibelimab. Checkpoint intends to address the feedback in a BLA
8-K
EX-99.1
0oak6zvsy
18 Dec 23
U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer
7:10am
8-K
EX-1.1
u2qngzfxie1 095r
21 Sep 20
Entry into a Material Definitive Agreement
5:26pm
8-K
EX-1.1
vw54ze
20 Nov 19
Entry into a Material Definitive Agreement
4:50pm
10-12G/A
EX-10.19
q4fbx3
19 Aug 16
Registration of securities (amended)
12:00am
10-12G
EX-10
8lnckl mr
11 Jul 16
Registration of securities
12:00am
10-12G
EX-10
nx2l3l
11 Jul 16
Registration of securities
12:00am
10-12G
EX-10
8fwvsv
11 Jul 16
Registration of securities
12:00am
10-12G
EX-10
oyidl8ln
11 Jul 16
Registration of securities
12:00am
10-12G
EX-10
7shnmymy
11 Jul 16
Registration of securities
12:00am